Atara Biotherapeutics, Inc.
NASDAQ:ATRA · NASDAQ Global Select
+$0.19 today
Vol 0.11M · Avg 1.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-84.9%
avg -184.8%
ROIC
222.7%
avg -32.4%
ROA
161.5%
avg -178.8%
Analysis
ROIC is currently the strongest return metric at 222.7% versus its period average of -32.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Anhco Nguyen | President, Chief Executive Officer & Director | $1.07M | — | 53 | $137,837.00 | 1.53% |
Alex Chapman | Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
Jim Sesic | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Yanina Grant-Huerta | Chief Accounting Officer & Principal Accounting Officer | — | — | 48 | $49,636.00 | 0.55% |
John Chao | Head of Legal | — | — | — | $88,762.00 | 0.99% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$5.60M
Sells
23
$3.87M
Net Sentiment
+$1.73M
Net buying
Most Active
Grant-Huerta Yanina
11 transactions
1–10 of 26
Analysis
Insiders reported 3 buys worth $5.60M and 23 sells worth $3.87M over the last 12 months. That adds up to net buying of $1.73M. Grant-Huerta Yanina was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$311.91M
Sutro Biopharma, Inc.
NASDAQ:STRO
$285.64M
MacroGenics, Inc.
NASDAQ:MGNX
$258.81M
Shattuck Labs, Inc.
NASDAQ:STTK
$233.53M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$155.72M
InflaRx N.V.
NASDAQ:IFRX
$130.09M
Champions Oncology, Inc.
NASDAQ:CSBR
$89.71M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.04M
Clene Inc.
NASDAQ:CLNN
$60.40M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.66M
Who manages ATRA?
Atara Biotherapeutics, Inc. (ATRA) lists 5 active executives. The top listed executive is Alex Chapman, Vice President of Corporate Communications & Investor Relations.
Are ATRA insiders buying or selling?
Recent insider activity shows net selling of $16.89M.
Explore More
Continue the stock analysis
Jump to another research area for this company.